Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Fundamental Analysis

USA - NASDAQ:SPRB - US85209E2081 - Common Stock

157.82 USD
+1.21 (+0.77%)
Last: 10/17/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SPRB. SPRB was compared to 534 industry peers in the Biotechnology industry. SPRB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SPRB has reported negative net income.
In the past year SPRB has reported a negative cash flow from operations.
In the past 5 years SPRB always reported negative net income.
In the past 5 years SPRB always reported negative operating cash flow.
SPRB Yearly Net Income VS EBIT VS OCF VS FCFSPRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -221.53%, SPRB is doing worse than 91.59% of the companies in the same industry.
SPRB has a Return On Equity of -366.75%. This is in the lower half of the industry: SPRB underperforms 74.02% of its industry peers.
Industry RankSector Rank
ROA -221.53%
ROE -366.75%
ROIC N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
SPRB Yearly ROA, ROE, ROICSPRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

SPRB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRB Yearly Profit, Operating, Gross MarginsSPRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

SPRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPRB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SPRB has more shares outstanding
SPRB has a worse debt/assets ratio than last year.
SPRB Yearly Shares OutstandingSPRB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SPRB Yearly Total Debt VS Total AssetsSPRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SPRB has an Altman-Z score of -17.85. This is a bad value and indicates that SPRB is not financially healthy and even has some risk of bankruptcy.
SPRB has a worse Altman-Z score (-17.85) than 83.55% of its industry peers.
SPRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.85
ROIC/WACCN/A
WACC9.42%
SPRB Yearly LT Debt VS Equity VS FCFSPRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SPRB has a Current Ratio of 2.60. This indicates that SPRB is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.60, SPRB is not doing good in the industry: 68.22% of the companies in the same industry are doing better.
A Quick Ratio of 2.60 indicates that SPRB has no problem at all paying its short term obligations.
SPRB has a Quick ratio of 2.60. This is in the lower half of the industry: SPRB underperforms 66.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
SPRB Yearly Current Assets VS Current LiabilitesSPRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SPRB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -396.54%.
Looking at the last year, SPRB shows a very negative growth in Revenue. The Revenue has decreased by -86.42% in the last year.
EPS 1Y (TTM)-396.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.79%
Revenue 1Y (TTM)-86.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SPRB will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.85% on average per year.
SPRB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y13.62%
EPS Next 2Y35.9%
EPS Next 3Y22.92%
EPS Next 5Y14.85%
Revenue Next Year-80.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y1.34%
Revenue Next 5Y-14.87%

3.3 Evolution

SPRB Yearly Revenue VS EstimatesSPRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2030 2031 2032 50M 100M
SPRB Yearly EPS VS EstimatesSPRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SPRB. In the last year negative earnings were reported.
Also next year SPRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRB Price Earnings VS Forward Price EarningsSPRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRB Per share dataSPRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40 -60 -80

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRB's earnings are expected to grow with 22.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.9%
EPS Next 3Y22.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (10/17/2025, 8:00:02 PM)

157.82

+1.21 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners21.05%
Inst Owner Change0%
Ins Owners2.32%
Ins Owner Change0%
Market Cap88.38M
Analysts43.33
Price Target10.2 (-93.54%)
Short Float %0.11%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.93%
Min EPS beat(2)-46.19%
Max EPS beat(2)82.06%
EPS beat(4)2
Avg EPS beat(4)-29.23%
Min EPS beat(4)-166.11%
Max EPS beat(4)82.06%
EPS beat(8)6
Avg EPS beat(8)-2.9%
EPS beat(12)9
Avg EPS beat(12)1.14%
EPS beat(16)12
Avg EPS beat(16)3.55%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-70.82%
Min Revenue beat(4)-100%
Max Revenue beat(4)-22.79%
Revenue beat(8)4
Avg Revenue beat(8)-0.65%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)566.67%
PT rev (3m)566.67%
EPS NQ rev (1m)-10103.3%
EPS NQ rev (3m)-10103.3%
EPS NY rev (1m)-11084.2%
EPS NY rev (3m)-11084.2%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-37.5%
Revenue NY rev (3m)-37.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.04
P/FCF N/A
P/OCF N/A
P/B 6.71
P/tB 6.71
EV/EBITDA N/A
EPS(TTM)-86
EYN/A
EPS(NY)-11.54
Fwd EYN/A
FCF(TTM)-91.88
FCFYN/A
OCF(TTM)-91.88
OCFYN/A
SpS2.32
BVpS23.54
TBVpS23.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -221.53%
ROE -366.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-72.45%
ROA(5y)-53.79%
ROE(3y)-104.69%
ROE(5y)-74.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -17.85
F-Score1
WACC9.42%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)65.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-396.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.79%
EPS Next Y13.62%
EPS Next 2Y35.9%
EPS Next 3Y22.92%
EPS Next 5Y14.85%
Revenue 1Y (TTM)-86.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-80.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y1.34%
Revenue Next 5Y-14.87%
EBIT growth 1Y-6.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.89%
OCF growth 3YN/A
OCF growth 5YN/A